Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551951 · ClinicalTrials.gov registry record
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
A clinical trial of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- 320
- Enrollment target
- 1
- Study location
NCT03551951: Recruiting study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by University of Missouri-Columbia.
NCT03551951 is a study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 320 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03551951, a study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies and improve screening.
Primary Outcome
Quantify the number of CTC and DTC in urine
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Test for circulating tumor cells, DNA alterations
Study Locations (1)
Missouri
- Harry S Truman Veterans Memorial Hospital - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2027-12-30 |
What NCT03551951 shows while recruiting
NCT03551951 is an observational study that tracks outcomes without assigning an intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower).
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Test for circulating tumor cells, DNA alterations is the first listed.
NCT03551951 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03551951 about?
NCT03551951 is a clinical study titled "Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow". Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may cure patients at an early stage. Circulating and disseminated ...
What is the current status of trial NCT03551951?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2016-07-01. Estimated completion is 2027-12-30.
What conditions does trial NCT03551951 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT03551951?
The interventions under investigation include: Test for circulating tumor cells, DNA alterations (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03551951?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03551951 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03551951's enrollment target sits among peer trials
320 114th of 454 higher than 339 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT04606446 · 320 participants · Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI